Skip to main content

Table 2 Clinical characteristics of cancer by cancer type

From: Disability, psychological distress and quality of life in relation to cancer diagnosis and cancer type: population-based Australian study of 22,505 cancer survivors and 244,000 people without cancer

  Prostate Breast Melanoma Colorectal NHL Lung Kidney Uterus Bladder Leukaemia Thyroid Multiple myeloma Oesophagus Other cancer Any cancer
n 5854 4330 3398 3011 814 493 486 479 398 376 338 183 83 2262 22,505
Median time since diagnosis (years) 3.4 4.9 4.5 3.8 3.6 2.1 4.0 4.0 4.4 3.7 4.0 2.9 2.2 3.7 3.9
Time since diagnosis (years)
 < 1 16.2% 10.3% 12.7% 16.6% 15.6% 29.8% 14.8% 15.5% 14.1% 16.8% 16.6% 17.5% 38.6% 16.8% 15.0%
 1 to < 5 50.1% 41.0% 42.6% 43.7% 45.1% 45.6% 44.0% 41.5% 41.5% 48.4% 42.6% 59.6% 36.1% 44.7% 45.0%
 5 to < 10 27.2% 37.6% 34.6% 31.5% 31.7% 22.1% 32.5% 34.0% 36.7% 29.0% 32.3% 20.8% 24.1% 29.5% 31.7%
 10 or more 6.5% 11.1% 10.1% 8.2% 7.6% 2.4% 8.6% 9.0% 7.8% 5.9% 8.6% 2.2% 1.2% 8.9% 8.4%
Stage
 localised to tissue or origin 56.2% 59.6% 88.9% 41.1% N/A 43.6% 74.9% 64.7% 54.0% N/A 67.5% N/A 49.4% 38.5% 55.6%
 regional spread, adjacent organs and/or regional lymph nodes 6.7% 32.4% 4.5% 45.3% N/A 25.4% 14.6% 21.3% 10.3% N/A 15.4%   27.7% 22.7% 18.9%
 distant metastases 0.7% 2.3% 1.3% 5.1% N/A 13.4% 2.3% 3.8% 2.0% N/A 3.0% N/A 4.8% 10.2% 3.1%
 unknown 36.5% 5.7% 5.2% 8.6% N/A 17.7% 8.2% 10.2% 33.7% N/A 14.2% N/A 18.1% 28.6% 22.5%
Recent treatment
 No 78.7% 71.5% 92.9% 80.1% 73.8% 64.9% 87.0% 87.3% 81.2% 70.7% 85.2% 35.0% 65.1% 78.4% 79.1%
 Yes 21.3% 28.5% 7.1% 19.9% 26.2% 35.1% 13.0% 12.7% 18.8% 29.3% 14.8% 65.0% 34.9% 21.6% 20.9%
  1. Stage for any cancer includes solid cancers only (prostate, breast, melanoma, colorectal, lung, kidney, uterus, bladder, thyroid and oesophagus)
  2. Proportions of unknown stage were 85.6%, 93.9% and 89.1% for non-Hodgkin’s lymphoma (NHL), leukaemia and multiple myeloma, respectively
  3. Diagnosis codes grouped under “other cancers”, and the corresponding numbers of participants are included in Additional file 2: Table S1
  4. The numbers of participants with sex-specific cancers included 28 males with breast cancer and 1 female with prostate cancer. Those were excluded from subsequent prevalence ratio analyses